Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Why You Should Consider Buying Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.
New Strong Buy Stocks for January 10th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Zacks.com featured expert Kevin Matras highlights: Amedisys, Foot Locker, Shoe Carnival, Tractor Supply and Caseys General Stores
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Amedisys, Foot Locker, Shoe Carnival, Tractor Supply and Caseys General Stores
Zacks.com featured expert Kevin Matras highlights: Helmerich & Payne, Manulife Financial, HEICO, Amedisys and Titan Machinery
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Helmerich & Payne, Manulife Financial, HEICO, Amedisys and Titan Machinery
Zacks.com featured expert Kevin Matras highlights: BJ's Restaurants, O'Reilly Automotive, Amedisys, HCA Healthcare and Toyota Motor
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: BJ's Restaurants, O'Reilly Automotive, Amedisys, HCA Healthcare and Toyota Motor
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
5 Quality Stock Picks Based on DuPont Analysis
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived from the DuPont way.
Buy These 5 Low Leverage Stocks to Stay Away From Debt Traps
by Zacks Equity Research
Since debt-ridden companies are more vulnerable at times of crisis, it is better to avoid those. Of course, entirely avoiding companies with debt loads is virtually impossible.
Here Are 5 Stocks With Amazing Interest Coverage Ratio
by Zacks Equity Research
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charged on its debt.
Amedisys Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Amedisys has been struggling lately, but the selling pressure may be coming to an end soon.
Has the Trade Debacle Ended for US MedTech Space? 3 Picks
by Sreyoshi Mukherjee
As the trade war fears slowly dissipate, let's take a look at three profitable U.S. MedTech picks.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.
Amedisys (AMED) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amedisys (AMED) closed at $114.79, marking a +0.88% move from the previous day.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Computer Programs and Systems, BioTelemetry, HMS, Amedisys and Molina Healthcare
5 Great Healthcare Stocks to Buy for 2019
by Swarup Gupta
Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.
5 Nasdaq Composite Stocks That Braved the Index's Bloodbath
by Nalak Das
Despite a plummeting Nasdaq Composite, a few companies have survived the turbulence because of their internal strengths.
Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty
by Madhura Bhattacharyya
Let's take a look at seven growth stocks that are poised to offer impressive returns in 2019.
Zacks.com featured highlights include: Amedisys, Marine Products, Foot Locker, Systemax and Comfort Systems
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, Marine Products, Foot Locker, Systemax and Comfort Systems
Ride on DuPont Analysis With 5 Top Stocks
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.